← back to search

Ruin Moaddel

National Institutes of Health · US
Area of research
Molecular Biology · Pharmacology
Research interest
Research interests include Treatment of Major Depression, Receptor Mechanisms and Signaling, Tryptophan and brain disorders, and Nicotinic Acetylcholine Receptors Study.
h-index
61
citations
16,063
works
322
NIH funding
primary concept
email

Recent publications

Proteomic analysis of APOEε4 carriers implicates lipid metabolism, complement and lymphocyte signaling in cognitive resilience
Molecular Neurodegeneration 2024cited by 14position: middledoi
Plasma proteins related to inflammatory diet predict future cognitive impairment
Molecular Psychiatry 2023cited by 42position: middledoi
Experimenters’ sex modulates mouse behaviors and neural responses to ketamine via corticotropin releasing factor
Nature Neuroscience 2022cited by 133position: middledoi
Proteomics in aging research: A roadmap to clinical, translational research
Aging Cell 2021cited by 136position: firstdoi
Cross-Laboratory Standardization of Preclinical Lipidomics Using Differential Mobility Spectrometry and Multiple Reaction Monitoring
Analytical Chemistry 2021cited by 97position: middledoi
Discovery proteomics in aging human skeletal muscle finds change in spliceosome, immunity, proteostasis and mitochondria
eLife 2019cited by 226position: middledoi
High-potency ligands for DREADD imaging and activation in rodents and monkeys
Nature Communications 2019cited by 216position: middledoi
Antidepressant-relevant concentrations of the ketamine metabolite (2 <i>R</i> ,6 <i>R</i> )-hydroxynorketamine do not block NMDA receptor function
Proceedings of the National Academy of Sciences 2019cited by 157position: middledoi
Serum lipids in adults with late age-related macular degeneration: a case-control study
Lipids in Health and Disease 2019cited by 21position: middledoi
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Pharmacological Reviews 2018cited by 1,241position: middledoi
Plasma proteomic signature of age in healthy humans
Aging Cell 2018cited by 571position: middledoi
Resveratrol Improves Vascular Function and Mitochondrial Number but Not Glucose Metabolism in Older Adults
The Journals of Gerontology Series A 2017cited by 101position: middledoi
Synthesis and <i>N</i>-Methyl-<scp>d</scp>-aspartate (NMDA) Receptor Activity of Ketamine Metabolites
Organic Letters 2017cited by 84position: middledoi
Trauma Interventions using Mindfulness Based Extinction and Reconsolidation (TIMBER) psychotherapy prolong the therapeutic effects of single ketamine infusion on post-traumatic stress disorder and comorbid depression: a pilot randomized, placebo-controlled, crossover clinical trial
Asia Pacific Journal of Clinical Trials Nervous System Diseases 2017cited by 47position: middledoi
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Nature 2016cited by 1,586position: middledoi
Child Stunting is Associated with Low Circulating Essential Amino Acids
EBioMedicine 2016cited by 342position: middledoi
A High-Fat Diet and NAD + Activate Sirt1 to Rescue Premature Aging in Cockayne Syndrome
Cell Metabolism 2014cited by 352position: middledoi
Resveratrol Prevents β-Cell Dedifferentiation in Nonhuman Primates Given a High-Fat/High-Sugar Diet
Diabetes 2013cited by 137position: middledoi
SIRT1 Is Required for AMPK Activation and the Beneficial Effects of Resveratrol on Mitochondrial Function
Cell Metabolism 2012cited by 1,553position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Luigi Ferrucci · Banyan Biomarkers (United States)7 papers (2016–2024)Todd D. Gould · University of Maryland, Baltimore5 papers (2016–2022)Panos Zanos · University of Cyprus5 papers (2016–2022)Patrick J. Morris · National Institutes of Health5 papers (2016–2019)Carlos A. Zarate · National Institutes of Health5 papers (2016–2022)Craig J. Thomas · National Institutes of Health4 papers (2016–2019)Richard D. Semba · Johns Hopkins University4 papers (2016–2021)Scott M. Thompson · University of Maryland, Baltimore3 papers (2016–2022)Rafael de Cabo · National Institutes of Health3 papers (2012–2014)Polymnia Georgiou · University of Wisconsin–Milwaukee3 papers (2016–2022)Edna F. R. Pereira · University of Maryland, Baltimore3 papers (2018–2022)Edson X. Albuquerque · University of Maryland, Baltimore3 papers (2016–2019) · 3 papers (2016–2022)Zhongsheng Peng · Johns Hopkins Medicine2 papers (2023–2024)Kathleen M. Hayden · Department of Health2 papers (2023–2024)Jaclyn N. Highland · University of Maryland, Baltimore2 papers (2018–2022)Myriam Gorospe · National Institutes of Health2 papers (2019–2021)David Sinclair · Harvard University2 papers (2012–2017)Michelle Shardell · Human Genome Sciences (United States)2 papers (2016–2019) · 2 papers (2019–2022)